The accumulated experience with the use of mycophenolate mofetil in primary glomerulonephritis

Expert Opinion on Investigational Drugs

Volumn 19, Issue 5, 2010, Pages 673-687

  Koukoulaki, Maria ^a   Goumenos, Dimitrios S ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Focal segmental glomerulosclerosis; Glomerulonephritis; IgA nephropathy; Membranous nephropathy; Minimal change disease; Mycophenolate mofetil; Nephrotic syndrome

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; TACROLIMUS;

ABDOMINAL PAIN; COHORT ANALYSIS; COLITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG WITHDRAWAL; ENTERITIS; EPIGASTRIC PAIN; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IDIOPATHIC MEMBRANOUS NEPHROPATHY; IMMUNOGLOBULIN A NEPHROPATHY; INFECTION; LEUKOPENIA; LOW DRUG DOSE; LUNG TUBERCULOSIS; MEMBRANOUS GLOMERULONEPHRITIS; MILIARY TUBERCULOSIS; MINIMAL CHANGE GLOMERULONEPHRITIS; MONOTHERAPY; NAUSEA; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PNEUMONIA; PROTEINURIA; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; FIBROSIS; GLOMERULONEPHRITIS; HUMANS; MYCOPHENOLIC ACID; PROTEINURIA;

EID: 77951490147     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543781003765461     Document Type: Review

References (72)

1. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997;63(1):39-47
2. Fujihara CK, Malheiros DM, Zatz R, et al. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998;54(5):1510-1519
3. Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998;31(2):213-217
4. Sollinger HW. Mycophenolate mofetil. Kidney Int Suppl 1995;52:S14-7
5. Danovitch GM. Immunosuppressive medications for renal transplantation: a multiple choice question. Kidney Int 2001;59(1):388-402
6. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47(2-3):85-118
7. Romero F, Rodriguez-Iturbe B, Parra G, et al. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999;55(3):945-955
8. Bloudickova S, Rajnoch J, Lodererova A, et al. Mycophenolate mofetil ameliorates accelerated progressive nephropathy in rat. Kidney Blood Press Res 2006;29(1):60-66
9. Kramer S, Loof T, Martini S, et al. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril. Am J Physiol Renal Physiol 2005;289(2):F359-68
10. Luca ME, Paul LC, van Der Wal AM, et al. Treatment with mycophenolate mofetil attenuates the development of Heymann nephritis. Exp Nephrol 2000;8(2):77-83
11. Utimura R, Fujihara CK, Mattar AL, et al. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003;63(1):209-216 (Pubitemid 35463923)
12. Wu YG, Lin H, Qi XM, et al. Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes. Int Immunopharmacol 2006;6(3):445-453
13. Wu Y, Dong J, Yuan L, et al. Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy. Cytokine 2008;44(1):85-91
14. Patari-Sampo A, Ihalmo P, Holthofer H. Molecular basis of the glomerular filtration: nephrin and the emerging protein complex at the podocyte slit diaphragm. Ann Med 2006;38(7):483-492
15. Nakhoul F, Ramadan R, Khankin E, et al. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies. Am J Physiol Renal Physiol 2005;289(4):F880-90
16. Badid C, Vincent M, McGregor B, et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000;58(1):51-61
17. Dubus I, Vendrely B, Christophe I, et al. Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int 2002;62(3):857-867
18. Bargman JM. Management of minimal lesion glomerulonephritis: evidence-based recommendations. Kidney Int Suppl 1999;70:S3-16
19. Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 2001;16(3):271-282
20. Meyrier A, Noel LH, Auriche P, et al. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int 1994;45(5): 1446-1456
21. Day CJ, Cockwell P, Lipkin GW, et al. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002;17(11):2011-2013
22. Gellermann J, Querfeld U. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 2004;19(1):101-104
23. Mendizabal S, Zamora I, Berbel O, et al. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol 2005;20(7):914-919
24. Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002;61(3): 1098-1114
25. Pesavento TE, Bay WH, Agarwal G, et al. Mycophenolate therapy in frequently relapsing minimal change disease that has failed cyclophosphamide therapy. Am J Kidney Dis 2004;43(3):e3-6
26. Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007;2(3):445-453
27. Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 2008;23(11):2013-2020
28. Korbet SM. Treatment of primary focal segmental glomerulosclerosis. Kidney Int 2002;62(6):2301-2310
29. Chun MJ, Korbet SM, Schwartz MM, et al. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004;15(8):2169-2177
30. Burgess E. Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int Suppl 1999;70:S26-32
31. Cameron JS. Focal segmental glomerulosclerosis in adults. Nephrol Dial Transplant 2003;18 (Suppl 6):vi45-51
32. Ponticelli C, Rizzoni G, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993;43(6): 1377-1384
33. Cattran DC. Cyclosporine in the treatment of idiopathic focal segmental glomerulosclerosis. Semin Nephrol 2003;23(2):234-241 (Pubitemid 36397106)
34. Goumenos DS, Tsagalis G, El Nahas AM, et al. Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study. Nephron Clin Pract 2006;104(2):c75-82 (Pubitemid 44448603)
35. Cattran DC, Wang MM, Appel G, et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004;62(6):405-411 (Pubitemid 39654577)
36. Segarra A, Amoedo ML, Martinez Garcia JM, et al. Efficacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary glomerulonephritis-a multicenter study. Nephrol Dial Transplant 2007;22(5):1351-1360 (Pubitemid 47072223)
37. Montané B, Abitbol C, Chandar J, et al. Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 2003;18(8):772-777 (Pubitemid 36949963)
38. Dimkovic N, Jovanovic D, Kovacevic Z, et al. Mycophenolate mofetil in high-risk patients with primary glomerulonephritis: results of a 1-year prospective study. Nephron Clin Pract 2009;111(3):c189-96
39. Senthil Nayagam L, Ganguli A, Rathi M, et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant 2008;23(6):1926-1930 (Pubitemid 351768140)
40. Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 2008;3(3):905-919
41. Ponticelli C, Zucchelli P, Passerini P, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989;320(1):8-13 (Pubitemid 19033056)
42. Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007;18(6):1899-1904 (Pubitemid 46870326)
43. Goumenos DS, Kalliakmani P, Tsakas S, et al. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin Nephrol 2004;61(1):17-24 (Pubitemid 38100839)
44. Alexopoulos E, Papagianni A, Tsamelashvili M, et al. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant 2006;21(11):3127-3132 (Pubitemid 44567084)
45. Miller G, Zimmerman R III, Radhakrishnan J, et al. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000;36(2):250-256 (Pubitemid 30485832)
46. Polenakovic M, Grcevska L, Dzikova S. Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy. Nephrol Dial Transplant 2003;18(6):1233-1234 (Pubitemid 36722535)
47. Ballarin J, Poveda R, Ara J, et al. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol Dial Transplant 2007;22(11):3196-3201 (Pubitemid 350202550)
48. Branten AJ, du Buf-Vereijken PW, Vervloet M, et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 2007;50(2):248-256
49. Dussol B, Morange S, Burtey S, et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis 2008;52(4):699-705
50. Chan TM, Lin AW, Tang SC, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton) 2007;12(6):576-581 (Pubitemid 350059122)
51. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987;64(245):709-727
52. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002;347(10):738-748
53. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol 2005;16(7):2088-2097
54. D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004;24(3):179-196
55. Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol 2005;18(5):503-512
56. Chen X, Chen P, Cai G, et al. A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy. Zhonghua Yi Xue Za Zhi 2002;82(12):796-801
57. Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004;65(5): 1842-1849
58. Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005;20(10):2139-2145
59. Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005;68(2):802-812
60. Xu G, Tu W, Jiang D, et al. Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis. Am J Nephrol 2009;29(5):362-367
61. Rasche FM, Keller F, von Muller L, et al. Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathy. J Nephrol 2006;19(4):465-472
62. Tan CH, Loh PT, Yang WS, et al. Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review. Singapore Med J 2008;49(10):780-785
63. Davies NM, Grinyo J, Heading R, et al. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant 2007;22(9):2440-2448
64. Selbst MK, Ahrens WA, Robert ME, et al. Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil. Mod Pathol 2009;22(6):737-743
65. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998;65(11):1450-1454
66. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20(5):1103-1112
67. Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997;175(4):901-904
68. Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 2002;35(1):53-61
69. Lv J, Zhang H, Cui Z, et al. Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. Nephrol Dial Transplant 2008;23(9):2868-2872
70. O'Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006;25(10):1186-1191
71. Robson R, Cecka JM, Opelz G, et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005;5(12):2954-2960
72. Briggs WA, Choi MJ, Scheel PJ Jr. Follow-up on mycophenolate treatment of glomerular disease. Am J Kidney Dis 1998;31(5):898-899